Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Cogent Biosciences, Inc. Logo
A clinical-stage biotech company developing precision therapies for genetic diseases.
United States of America
COGT
Coherus Oncology, Inc. Logo
Biopharmaceutical company developing and commercializing immuno-oncology therapies.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
A biopharmaceutical company developing abuse-deterrent pain management medications.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops plant-derived collagen for 3D bioprinting of tissues and organs.
United States of America
CLGN
COMPASS Pathways plc Logo
Develops psilocybin treatments for difficult-to-treat mental health conditions.
United States of America
CMPS
Compass Therapeutics, Inc. Logo
Clinical-stage biopharma developing antibody-based therapeutics for oncology.
United States of America
CMPX
Connect Biopharma Holdings Ltd Logo
A clinical-stage biopharma developing therapies for T cell-driven inflammatory diseases.
United States of America
CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX
Contineum Therapeutics, Inc. Logo
Clinical-stage biopharma developing oral small molecule therapies for NI&I conditions.
United States of America
CTNM
Corbus Pharmaceuticals Holdings, Inc. Logo
Clinical-stage biopharma developing targeted therapies for oncology and obesity.
United States of America
CRBP

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.